Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MPC 9055

Drug Profile

MPC 9055

Alternative Names: MPC-9055; Vivecon

Latest Information Update: 01 Sep 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Myriad Pharmaceuticals
  • Developer Myrexis
  • Class Antiretrovirals; Small molecules
  • Mechanism of Action Capsid protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • Available For Licensing Yes - HIV infections

Highest Development Phases

  • Suspended HIV-1 infections

Most Recent Events

  • 11 Feb 2009 Pharmacodynamics data from an in vitro study in HIV-1 infections presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)
  • 11 Feb 2009 Adverse events & pharmacokinetics data from a phase I trial in Healthy volunteers presented at the 16th Conference on Retroviruses and Opportunistic Infections (CROI-2009)
  • 31 Jan 2008 Phase-I clinical trials in HIV-1 infections treatment in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top